Shares of Regenxbio Inc. (NASDAQ:RGNX) saw unusually-high trading volume on Monday . Approximately 136,513 shares were traded during trading, a decline of 10% from the previous session’s volume of 151,596 shares.The stock last traded at $12.32 and had previously closed at $12.44.

RGNX has been the subject of several research reports. Zacks Investment Research downgraded Regenxbio from a “hold” rating to a “sell” rating in a research note on Friday, August 12th. Piper Jaffray Cos. reiterated a “buy” rating and set a $33.00 price target on shares of Regenxbio in a research note on Tuesday, July 5th. Finally, Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.75.

The company has a 50-day moving average of $9.70 and a 200 day moving average of $10.91. The company’s market capitalization is $324.73 million.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Analysts expect that Regenxbio Inc. will post ($2.37) earnings per share for the current year.

An institutional investor recently raised its position in Regenxbio stock. RS Investment Management Co. LLC boosted its position in shares of Regenxbio Inc. (NASDAQ:RGNX) by 11.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 746,592 shares of the company’s stock after buying an additional 75,810 shares during the period. RS Investment Management Co. LLC owned approximately 2.84% of Regenxbio worth $12,393,000 at the end of the most recent reporting period.

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.